In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients.
28 May 2009
1 June 2009
Cancer Research Technology, a British cancer charity, is to fund clinical trials of a drug owned by GlaxoSmithKline (GSK), in a groundbreaking programme to develop promising experimental medicines that are neglected due to limited corporate funding.
21 May 2009
Neil Darwent and Roger Cooper of GSK Biologicals talk to Pharm Exec Europe about the company's new, state-of-the-art approach to clinical trials in Africa.
US pharma CEO salaries are still dwarfing the earnings of their European counterparts, but, with the industry and the economy currently in crisis, Jacky Law asks how long this can continue.
You know those loud soundtracks and distracting visuals during the safety information in your TV ads? Critics have been complaining about them, and new draft guidance from FDA is calling them a "no-no."
Marketers fear a Catch-22 if they have to write research summaries that FDA considers illegal promotion.
Defining, evaluating, and utilizing the Target Product Profile.
As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.
Interstitial Page
New prescriptions for antiviral treatments get huge boost due to H1N1 epidemic. Numbers exceed those seen during this year's influenza season, and the numbers are climbing.
As the US government weighs its options on whether to commission a vaccine for the new H1N1 strain of influenza, pharma companies gear up for a possible epidemic.
Ortho-McNeil is reaching out to the adult ADHD segment through the popular social networking site. The plan is to grow followers through education and unbranded information. Pharm Exec takes a look at the new site.
Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line.
The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market.
After last week’s flurry of FDA warning letters directed at companies marketing through search ads, industry is left wondering what can be done be done to target patients online?
In an effort to realign its sales division to reflect the current pharma environment-smaller, faster, better-Johnson & Johnson is trimming its sales force.
Reflector points to a number of recent alarm signals that have seen European pharma move further towards dangerous territory.
Maureen Regan
WOTY- Podcast-Howson
Woty-Podcast-Sibley
Just two months after the purchase of Wyeth, Pfizer breaks its research division into two-one for large molecules and vaccines, and another for small molecules-with Wyeth and Pfizer execs at the helms.
Launching a product? Your competition likely plans to interfere. Here's how to counter a counter-launch.
Protecting Sensitive Information in Life Sciences Organizations: Top Three Misconceptions that Put Companies at Risk-Brainloop Whitepaper
In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.
Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle.
